Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Auxilium Pharmaceuticals Inc Reaffirms FY 2013 Guidance-Conference Call

Thursday, 14 Mar 2013 08:00am EDT 

Auxilium Pharmaceuticals Inc announced that for fiscal 2013, it expects total revenues of $325 million to $355 million with Testim revenues of $250 million to $265 million, US XIAFLEX revenues of $65 million to $75 million and non-GAAP basis income to be $18 million to $23 million. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $336 million for fiscal 2013. 

Company Quote

0.28 +1.53%
29 Aug 2014